AAP
PHAT icon

Arax Advisory Partners’s Phathom Pharmaceuticals PHAT Stock Holding History

Arax Advisory Partners’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6
Closed -$100 – 4199
2025
Q4 		$100 Sell
6
-53
-90% -$757 ﹤0.01% 3825
2025
Q3 		$695 Buy
+59
New +$609 ﹤0.01% 3326
2024
Q4 		– Sell
-17
Closed -$308 – 2668
2024
Q3 		$308 Hold
17
– – ﹤0.01% 2470
2024
Q2 		$176 Buy
+17
New +$175 ﹤0.01% 2452

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Arax Advisory Partners's PHAT Position: Q1 2026 in Review

Arax Advisory Partners sold out of Phathom Pharmaceuticals (PHAT) in Q1 2026, closing a stake of 6 shares — an estimated $100 sold.

Arax Advisory Partners first reported a position in PHAT in Q2 2024 and held it in 4 quarters. The position peaked at $695 in Q3 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Arax Advisory Partners reported no remaining Phathom Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 6 Phathom Pharmaceuticals shares in Q1 2026, an estimated $100.
  • Arax Advisory Partners first reported a position in Phathom Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Arax Advisory Partners's Phathom Pharmaceuticals position peaked at $695 in Q3 2025.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.